GlassScriptPhysician profile
David Burl Duvall
NPI 1609005669
$2,287.01
in general payments reported to CMS, 2019-2025
13 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $78.86 · 2021: $68.98 · 2022: $243 · 2023: $94.73 · 2024: $25.93 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,423.65 | 2019-2022 | |
| Medtronic, INC. | $166.66 | 2025 | Transorb |
| Tela Bio, INC. | $165.96 | 2019 | |
| Smith+Nephew, INC. | $140.00 | 2019 | |
| Prytime Medical Devices, INC. | $93.61 | 2019 | |
| Abbvie INC. | $75.28 | 2023 | Strattice Reconstructive Tissue Matrix Bps |
| Integra Lifesciences Corporation | $55.53 | 2020 | |
| Tei Biosciences INC | $52.51 | 2019 | |
| Intuitive Surgical, INC. | $37.42 | 2025 | |
| Atricure, INC. | $25.93 | 2024 | |
| Medline Industries LP | $20.99 | 2019 | |
| Ardelyx, INC. | $19.45 | 2023 | Ibsrela |
| Kls-Martin L.P. | $10.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Duvall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.